Release Therapeutics Secures CHF 3.3 Million in Seed Funding
August 06, 2024 04:00 ET
|
Release Therapeutics SA
Release Therapeutics Secures CHF 3.3 Million in Seed Funding following first preclinical results in metachromatic leukodystrophy.
Release Therapeutics Announces New CEO to Drive Best-in-Class CNS Innovation
June 27, 2024 04:00 ET
|
Release Therapeutics SA
Release Therapeutics Announces New CEO to drive strategic pivot towards treating genetic disorders of the CNS without gene therapy